Worldwide Clinical Trials has brought on Hiromi Wakita, PhD, to lead the company’s operations in Japan as vice president of clinical operations.
Wakita began his career in regulatory affairs and has worked at several CROs. Before joining Worldwide, he led Japan-based clinical trial operations for CROs running Phase I-IV trials across various therapeutic areas as the Japan general manager for Clinipace.
He also has held Japan-based leadership roles at Mebix, INC Research, Quintiles Transnational Japan K.K, and Icon.
Wakita told us he is excited to join Worldwide at a 'pivotal moment' for clinical research in Japan.
“While the quality of clinical studies in Japan has always been, and remains, quite high, the traditionally time consuming, costly clinical research environment is changing drastically. Worldwide has comprehensive and strong operational capabilities, which are required as a global CRO, and also has the flexibility and entrepreneurial mindset of a midsized organization," he said.
"These attributes are critical as we establish our own capability and organization in Japan, with an emphasis on prioritizing new stream-lined procedures. We can provide our services for clients within a reasonable cost and timeline, generating the best outcome for patients, so they can receive drugs they need sooner and cheaper.
"I cannot wait to build our dedicated team in Japan swiftly and introduce our capability to customers who have an interest in drug development in Japan.”